Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV human cytomegalovirus immunoglobulin (pH4) after haploidentical allo-HSCT
CTR20180496Phase 2Completed
- Sponsor
- Chengdu Rongsheng Pharmaceutical
- Start
- Apr 2018
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of human cytomegalovirus immune globulin in cytomegalovirus disease (CMV), cytomegalovirus infection, sponsored by Chengdu Rongsheng Pharmaceutical. Started Apr 2018; status: completed.
02
Drugs
human cytomegalovirus immune globulin
03
Conditions
cytomegalovirus disease (CMV)cytomegalovirus infection
Beyond the preview
Go deeper on CTR20180496.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180496.